BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 32339387)

  • 1. COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin.
    Theoharides TC
    Biofactors; 2020 May; 46(3):306-308. PubMed ID: 32339387
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel coronavirus SARS-CoV-2 (Covid-19) dynamics inside the human body.
    Saha A; Saha B
    Rev Med Virol; 2020 Sep; 30(5):e2140. PubMed ID: 32686248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
    Nguyen AA; Habiballah SB; Platt CD; Geha RS; Chou JS; McDonald DR
    Clin Immunol; 2020 Jul; 216():108459. PubMed ID: 32418917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from dermatology about inflammatory responses in Covid-19.
    Criado PR; Pagliari C; Carneiro FRO; Quaresma JAS
    Rev Med Virol; 2020 Sep; 30(5):e2130. PubMed ID: 32656939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection.
    Ahlawat S; Asha ; Sharma KK
    Virus Res; 2020 Sep; 286():198103. PubMed ID: 32717345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug targets for COVID-19 therapeutics: Ongoing global efforts.
    Saxena A
    J Biosci; 2020; 45(1):. PubMed ID: 32661214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 infection and overactivation of Nlrp3 inflammasome as a trigger of cytokine "storm" and risk factor for damage of hematopoietic stem cells.
    Ratajczak MZ; Kucia M
    Leukemia; 2020 Jul; 34(7):1726-1729. PubMed ID: 32483300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2.
    Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C
    Signal Transduct Target Ther; 2020 May; 5(1):84. PubMed ID: 32467561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientific research progress of COVID-19/SARS-CoV-2 in the first five months.
    Li H; Liu Z; Ge J
    J Cell Mol Med; 2020 Jun; 24(12):6558-6570. PubMed ID: 32320516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin as candidate for supportive treatment of severe COVID-19.
    Ehrenreich H; Weissenborn K; Begemann M; Busch M; Vieta E; Miskowiak KW
    Mol Med; 2020 Jun; 26(1):58. PubMed ID: 32546125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19.
    Cheng H; Wang Y; Wang GQ
    J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of inhaled corticosteroids in asthma and coronavirus disease 2019: Keep calm and carry on.
    Lipworth B; Chan R; Kuo CR
    Ann Allergy Asthma Immunol; 2020 Nov; 125(5):503-504. PubMed ID: 32585180
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response.
    Ryan PM; Caplice N
    Open Heart; 2020 Jun; 7(1):. PubMed ID: 32532804
    [No Abstract]   [Full Text] [Related]  

  • 15. After 62 years of regulating immunity, dexamethasone meets COVID-19.
    Cain DW; Cidlowski JA
    Nat Rev Immunol; 2020 Oct; 20(10):587-588. PubMed ID: 32778829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covid-19: Time for a paradigm change.
    Buonaguro FM; Ascierto PA; Morse GD; Buonaguro L; Puzanov I; Tornesello ML; Bréchot C; Gallo RC
    Rev Med Virol; 2020 Sep; 30(5):e2134. PubMed ID: 32618072
    [No Abstract]   [Full Text] [Related]  

  • 17. A brief review of interplay between vitamin D and angiotensin-converting enzyme 2: Implications for a potential treatment for COVID-19.
    Malek Mahdavi A
    Rev Med Virol; 2020 Sep; 30(5):e2119. PubMed ID: 32584474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK Inhibition as a New Treatment Strategy for Patients with COVID-19.
    Seif F; Aazami H; Khoshmirsafa M; Kamali M; Mohsenzadegan M; Pornour M; Mansouri D
    Int Arch Allergy Immunol; 2020; 181(6):467-475. PubMed ID: 32392562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?
    Oscanoa TJ; Romero-Ortuno R; Carvajal A; Savarino A
    Int J Antimicrob Agents; 2020 Sep; 56(3):106078. PubMed ID: 32629115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of lethal human coronaviruses.
    Chen B; Tian EK; He B; Tian L; Han R; Wang S; Xiang Q; Zhang S; El Arnaout T; Cheng W
    Signal Transduct Target Ther; 2020 Jun; 5(1):89. PubMed ID: 32533062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.